Reviewing Pharming Group (PHGUF) & Gilla (GLLA)

Pharming Group (OTCMKTS:PHGUF) and Gilla (OTCMKTS:GLLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Pharming Group and Gilla, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 0 1 0 3.00
Gilla 0 0 0 0 N/A

Earnings & Valuation

This table compares Pharming Group and Gilla’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $101.24 million 6.41 -$90.37 million ($0.18) -6.22
Gilla $4.60 million 0.94 -$6.64 million N/A N/A

Gilla has lower revenue, but higher earnings than Pharming Group.


This table compares Pharming Group and Gilla’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group -36.30% -176.01% -26.20%
Gilla -137.19% N/A -130.57%

Risk and Volatility

Pharming Group has a beta of 2.81, indicating that its share price is 181% more volatile than the S&P 500. Comparatively, Gilla has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.


Pharming Group beats Gilla on 6 of the 8 factors compared between the two stocks.

Pharming Group Company Profile

Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Gilla Company Profile

Gilla Inc. engages in the manufacture, marketing, and distribution of generic and premium branded e-liquid used in vaporizers, electronic cigarettes, and other vaping hardware and accessories in Europe, Canada, and the United States. The company offers its products under the brand names of Spectrum Concentrates, Coil Glaze, Craft Vapes, Siren, The Drip Factory, Shake It, Surf Sauce, Ohana, Moshi, Crisp, Just Fruit, Vinto Vape, Vapor's Dozen, Enriched Vapor, and Crown E-liquid. Gilla Inc. sells its products through market channels, including vape shops, retail and wholesale distributors, convenience stores, and e-commerce Websites. The company is headquartered in Daytona Beach, Florida.

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.

Leave a Reply